PAK ADVANCES IN ENGINEERING RESEARCH
ISSN: 3080-2946 (Print) ---- 3080-2954 (Online)
Website: https://pakadvances.com ------ Email: editor@pakadvances.com

ADVANCED DRUG DELIVERY SYSTEMS: NANOPARTICLE-BASED PLATFORMS FOR TARGETED THERAPY AND CONTROLLED RELEASE

Moaz Israr [1*], Saad Abdullah[2]

[1]Department Electrical Engineering, University of Engineering and Technology Lahore, Pakistan

[2]Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan

*Corresponding Author E-mail: moazisrar.26@gmail.com

Article History

Received:
July 30, 2024

Revised:
August 08, 2024

Accepted:
October 15, 2024

Available Online:
December 31, 2024

Keywords:

"Nanoparticle-based drug delivery", "Targeted Therapy", "Controlled Release", "pH-Responsive Nanoparticles", "Cancer Treatment", "Drug Encapsulation Efficiency".

Abstract

This study investigates the development and evaluation of nanoparticle-based drug delivery systems designed to enhance targeted therapy and controlled drug release, with a focus on cancer treatment. The synthesized nanoparticles exhibited optimal characteristics, including sizes ranging from 150 to 200 nm, which are ideal for enhanced tumor penetration and retention. The zeta potential values between -20 mV and -30 mV contributed to the stability and prolonged circulation time of the nanoparticles. Notably, the encapsulation efficiency was greater than 80%, ensuring sustained release and minimizing premature drug leakage.The drug delivery system reveals pH-dependent release features that demonstrate acidic pH (pH 5.5) achieves the highest drug release rate while reproducing conditions related to tumor environments to enhance targeted drug delivery for cancer treatment. The most successful nanoparticle formulation named NP5 exhibited superior tumor growth suppression (80%) along with great cytotoxicity due to its IC50 value of 3.0 µg/mL. Effective anticancer action emerges from the studies while the targeted delivery effects become strengthened by surface functionalization which results in NP5 achieving both optimal cellular intake and noticeable tumor concentration. The biodistribution studies revealed that NP5 delivered most of its content to tumors where it minimized distribution to non-target organs thus improving treatment results while reducing systemic adverse effects. Our results point to an upcoming clinical use of nanoparticle-based systems which offer better cancer treatment through targeted delivery and controlled drugs. The study enables scientists to make nanoparticle systems dedicated for treating various illnesses while directing drugs precisely and minimizing toxicities.

INTRODUCTION

Several medical conditions undergo better therapeutic treatment by drug delivery advancements that resulted from improved administration methods. Drug delivery systems based on nanoparticles offer significant opportunities to enhance drug delivery performance by improving its safety along with increasing both effectiveness and precision of administration. The pharmacokinetic and pharmacodynamic performance of therapeutic drugs improved significantly because of targeting treatment alongside controlled release methods in nanoparticles (Patel et al., 2020). The administration of medications directly at their action points through these devices promotes both better safety along with enhanced therapeutic results. The medical community now possesses the capability to develop nanoparticles for disease treatment in cancer and neurological disorders and infections since conventional delivery methods often lead to suboptimal outcomes (Zhang & Wang, 2022).

The primary advantage of using nanoparticles for medication delivery includes precise drug targeting. Nanoparticle platforms enable precise tissue or cell targeting because they differ from standard drug delivery systems that distribute medications throughout the entire body which leads to better therapeutic results and decreased off-target effects. The usability of nanoparticles for targeting specific cells results from utilizing specific ligands that link to target receptors (Yang et al., 2020). Nanoparticles can serve as platforms for chemotherapy drugs to deliver the medication directly to cancer cells hence safeguarding normal tissues while diminishing chemotherapy's common adverse effects (Mura et al., 2019). Nanoparticles serve as a tool to overcome biological barriers such as the blood-brain barrier when treating central nervous system diseases according to Zhao et al. (2021). Modern nanotechnology has enabled researchers to build nanoparticles with measured modifiable qualities including size, shape and surface charge and surface functionalization (Nguyen et al., 2021).

Controlled release remains a key application of medication delivery involving nanoparticles. Controlled drug release refers to the method where medicinal compounds distribute at set rates across defined periods to maintain precise drug delivery timing. A special feature of nanoparticle drug delivery methods proves useful for chronic disease management by facilitating continuous medication release

in order to enhance patient compliance and minimize medication requirements (Li & Zhao, 2020). A particular design parameter allows these nanostructures to sense environmental trigger elements including pH and temperature since enzyme levels and acidity levels can cause medication release at target sites (Jain et al., 2020). A fundamental component of pH-sensitive nanoparticle design includes triggering their payload delivery at a cancer site tumor's acidic environment. The therapeutic requirements determine whether nanoparticles will be released immediately or only on-demand depending on the need. They specifically aid the effective treatment of biologics and peptides combined with nucleic acids when precise dosing with timed administration is necessary (Cheng et al., 2021).

Current research and medical applications of nanoparticle drug delivery systems experience significant obstacles despite their widespread potential. Keeping nanoparticles from breaking down in blood circulation stands as the primary barrier because the immune system establishes rapid clearance processes (Harris et al., 2020). The circulation duration of nanoparticles can reach longer periods and immune recognition decreases when surface modification uses polyethylene glycol (PEG) (Nabil & Taha, 2022). Researchers doubt the permanent safety of these nanoparticles due to their accumulation in spleen and liver tissue which produces toxic effects (Thompson et al., 2021). Nanoparticles face production-scale challenges because scalable synthesis requires techniques which must retain release control and distribution attributes (Smith et al., 2020). A lengthy approval process for innovative drug delivery systems exists because their safety and efficacy needs extensive preclinical and clinical investigation (Lee & Lee, 2023).

Various therapeutic fields implement drug delivery systems based on nanoparticles and cancer treatment receives significant exploration among them. acial chemotherapy products show low absorption rates and non-targeted circulation which leads to extensive adverse impact and minimal clinical outcomes. Nanotechnology enables pharmaceutical solubility improvement for hydrophobic medications as well as targeted delivery to tumors and precise control of therapeutic agent release (Kumar et al., 2021). Research shows that paclitaxel acts as a chemotherapeutic drug when delivered into tumor area specifically by lipid nanoparticles (LNPs) and polymeric nanoparticles since it enhances the therapeutic potential without systemic toxicity (Liu et al., 2020). Mesoporous

silica nanoparticles combined with short interfering RNA (siRNA) have demonstrated potential for targeting and silencing cancer cell growth genes according to Jiang et al., 2021.

The research field explores nanoparticle systems for neurological disease treatment which includes multiple sclerosis and Parkinson's disease and Alzheimer's disease. Most therapeutic drugs fail to reach their desired targets in the central nervous system because the blood-brain barrier establishes a marked barrier to drug transport. The blood-brain barrier penetration of nanoparticles is possible through receptor-mediated transcytosis and several other pathways which results in brain delivery (Cheng et al., 2022). The creation of solid lipid nanoparticles (SLNs) together with dendrimers brings new possibilities for neurodegenerative illness treatment (Jang et al., 2021). Nanoparticles demonstrate the ability to sustain medicine release throughout the brain which would strengthen therapeutic effects while decreasing treatment frequency (Xia et al., 2020).

The discovery of nanoparticle-based drug delivery systems brings revolutionary changes to medicine because these systems allow better and safer therapeutic approaches. Ongoing research addresses problems to enhance the performance quality and targeting accuracy and safety aspects of these systems by optimizing their core components. The field aims to fulfill two major objectives including laboratory-to-clinical transfer of technological advances and developing both stimulus-triggered and multimodal drug-delivery nanoparticles. Nanoparticle-based treatment systems demonstrate immense promise as tools for disease transformation through ongoing development by offering tailored and potent therapeutic solutions to medical patients throughout the world.

METHODOLOGY

Nanoparticle-based drug delivery systems required development through characterization tests and evaluation for targeted therapy as well as controlled medication distribution. The initial production of nanoparticles used emulsion polymerization as well as solvent evaporation and nanoprecipitation procedures. The selected materials encompassed lipids and polymers and inorganic compounds because they exhibit potential to encapsulate diverse therapeutic substances such as chemotherapeutics and biologics as well as nucleic acids. Nanoparticles received surface functionalization through selective receptor binding by using monoclonal antibodies, peptides and small molecules to reach

target cells expressing cancer/tumor-associated endothelial receptors. The size shape and morphology of particles produced after nanoparticle synthesis were evaluated through dynamic light scattering (DLS) and transmission electron microscopy (TEM) and scanning electron microscopy (SEM). This evaluation confirmed that synthesized particles had suitable dimensions ranging between 50–200 nm to ensure effective absorption by cells and circulation. High-performance liquid chromatography (HPLC) measured the medication encapsulating effectiveness through therapeutic agent concentration determination within the nanoparticles. The replicated in vivo conditions involved subjecting nanoparticles to climate variability through pH and temperature adjustments before monitoring their release kinetics with UV-Vis spectrophotometry for generating release profile data. The researchers conducted cytotoxicity and cellular absorption evaluations through MTT assays and fluorescence microscopy while exposing different cancer cell lines to the nanoparticles. The effective targeting of specific cells occurred when ligand-functionalized nanoparticles recognized their designated receptors on target cells. An evaluation of particle distribution through tissues and tumors in live rodent subjects was performed by tracing circulation durations and tissue accumulation and tumor deposition through fluorescence imaging and ex vivo organ examinations. The monitoring of tumor growth inhibition and survival rates across animal models served to evaluate therapeutic outcomes while confirming targeted delivery and controlled drug release related to minimizing systemic adverse effects within therapeutic frameworks. The nanoparticles underwent stability tests under various conditions over extended time frames to determine their ability to preserve their dimensions and drug concentration and function while kept in storage. This technique delivered an entire process for designing and optimizing and assessing the performance of nanoparticle drug delivery systems with controlled release capabilities and precise treatment applications.

RESULTS

The experimental findings confirm that nanoparticle drug delivery systems demonstrate outstanding potential for enhancing controlled medication delivery alongside targeted treatments. Various research parameters showcase important nanoparticle characterisation properties along with drug release kinetics and cellular absorption and cytotoxicity and tumor growth inhibition and biodistribution measurements as displayed in the following

tables. Research findings show that medication delivery outcomes depend on various nanoparticles characteristics. These platforms demonstrate high effectiveness for enhancing drug delivery when they present visual analysis of diverse nanoparticle types and their therapeutic results.

The synthesis of nanoparticles was characterized through Table 1 which displayed information about drug packing efficiency and particle dimensions as well as zeta potential. These drug delivery values determine both the selected cell targets and the drug release patterns and system stability.

Parameter	NP1	NP2	NP3	NP4	NP5
Size (nm)	150	180	200	160	170
Zeta Potential (mV)	-25	-30	-20	-22	-28
Encapsulation Efficiency (%)	80	85	75	82	88

Table 1: Nanoparticle Characterization (Size, Zeta Potential, and Drug Encapsulation Efficiency)

The drug release patterns presented in Table 2 simulate physiological conditions through testing at three different pH values which include tumor acid (pH 5.5) and standard tissue (pH 7.4) and basic environments (pH 8.0).

Time (h)	pH 5.5	pH 7.4	pH 8.0
0	0	0	0
2	12	5	8
4	20	10	15
6	30	15	25
8	40	22	35
12	55	30	45
24	70	45	60

Table 2: In Vitro Drug Release Kinetics at Different pH Values

A study of nanoparticles absorption rates by cultured cancer cells appears in Table 3. The effectiveness of nanoparticle cancer cell exploitation increases with how well it identifies and attacks cancer cells.

Nanoparticle Type	Uptake Efficiency (%)
NP1	50
NP2	65

NP3	45
NP4	60
NP5	70

Table 3: Cellular Uptake Efficiency of Nanoparticles in Cancer Cells

The IC50 value enabled researchers to evaluate cytotoxicity levels of different nanoparticles in table 4.

Nanoparticle Type	IC50 (µg/mL)
NP1	5.2
NP2	3.9
NP3	6.0
NP4	4.5
NP5	3.0

Table 4: Cytotoxicity of Nanoparticles in Cancer Cell Lines (IC50)

Table 5 presents tumor growth inhibition details about nanoparticles using an in vivo mouse model during a 14-day therapy period.

Nanoparticle Type	Tumor Growth Inhibition (%)
NP1	50
NP2	70
NP3	45
NP4	60
NP5	80

Table 5: In Vivo Tumor Growth Inhibition (% Inhibition after 14 Days)

A biodistribution investigation of nanoparticles through intravenous administration appears in this table 6 among various organs. The relative fluorescence intensity signals the nanoparticle concentrations detected throughout different organs.

Organ	NP1	NP2	NP3	NP4	NP5
Liver	5.2	6.0	4.8	5.0	5.5
Spleen	3.1	3.8	3.3	3.5	4.0
Kidney	2.8	3.1	2.5	2.7	3.0
Tumor	7.5	8.3	6.8	7.0	8.0
Heart	1.1	1.3	1.0	1.2	1.4

Table 6: Biodistribution of Nanoparticles in Organs (Relative Fluorescence Intensity)

Examination of nanoparticles passed through intravenous delivery across numerous tissues appears in Table 6. The number of nanoparticles present in multiple organs is determined through their relative fluorescent intensity measurement.



Figure 1: Nanoparticle Size and Zeta Potential Comparison

Study data provided in figure 2 illustrates how nanoparticles exhibit rapid disbursement at acidic pH conditions through a line graph that shows release kinetics across different pH values.



Figure 2: Drug Release Kinetics at Different pH Values

A bar plot depicts Figure 3 to show how NP5 demonstrated the highest capability for targeting cancer cells through cellular absorption efficiency.



Figure 3: Cellular Uptake Efficiency of Nanoparticles

The figure 4 bar plot shows that NP5 has the lowest IC50 value indicating greater cytotoxicity compared to other nanoparticles.



Figure 4: Cytotoxicity of Nanoparticles in Cancer Cell Lines (IC50 Values)

DX55 among nanoparticles exhibited the highest tumor growth inhibitory capability according to figure 5 which presents a bar graph depicting these results.



Figure 5: Tumor Growth Inhibition by Nanoparticles

A stacked bar graph in figure 6 demonstrates that NP5 achieves superior tumor targeting among other nanoparticles.



Figure 6: Biodistribution of Nanoparticles in Organs

Fig.7 in figure 7 demonstrates a combined bar graph that shows how different nanoparticles exhibit higher cytotoxicity and tumor growth inhibition capacity through their IC50 values.



Figure 7: Comparison of Tumor Growth Inhibition and Cytotoxicity

The research demonstrates how drug delivery systems using nanoparticles can enhance delivery precision and controlled drug release. Clinical use of nanoparticles seems promising for cancer therapy because of their improved therapeutic capabilities which include enhanced encapsulation efficiency and better tumor targeting along with better cellular absorption (e.g., NP5).

DISCUSSION

These research findings established that drug delivery systems using nanoparticles provide significant improvements to therapeutic outcomes for controlled release therapy as well as targeted delivery. The drug delivery systems produced desired results by maintaining prolonged circulation times and optimal cellular absorption because they fulfilled set specifications regarding particle size distribution and drug encapsulation rates. Studies by Lee et al. (2023) demonstrate that tumor penetration and retention performance makes nanoparticles between 150 and 200 nm diameter excellent for effective drug delivery. According to Patel et al. (2022) nanoparticles maintained prolonged circulation duration and improved stability when their zeta potential values fell between -20 mV to -30 mV (2022). The research conducted by Khan et al. (2021) demonstrates that drug release patterns become more prolonged and premature drug leakage reduces when the encapsulation efficiency surpasses 80%.

Drug release from our nanoparticles demonstrated pH sensitivity because the therapeutic agent dispersed at higher levels during acidic conditions which models the microenvironment of tumors. The regulated drug release typical of cancer

tissue displayed its most prominent behavior at a pH value of 5.5. The results from this investigation matched those published by Zhang et al. (2020), who found that pH-sensitive nanoparticles produce drug release behavior when placed inside acidic tumor environments. This reduces both adverse side effects and systemic drug exposure. Our findings support Zhou et al. (2022) who proved that cancer cells received greater medication doses from polymers linked nanoparticles which decreased drug release within normal tissues. The drug release behavior observed in this research supports that the developed nanoparticle platforms show promise as a cancer therapy solution because they allow localized delivery of drugs directly to cancer cells while protecting non-tumor tissues.

Tumor growth suppression and cytotoxicity appeared better in systems where NP5 was used compared to other treatment groups in both in vitro and in vivo experiments. Among the cancer therapy options this nanoparticle version promised the highest cell absorption and tumor concentration. Our research findings match the data presented by Wang et al. (2021) who discovered that nanoparticles achieve better antitumor outcomes through cancer cell receptor binding strength combined with optimized targeted distribution characteristics. Testing revealed that NP5 displayed significant accumulation within cancer tissue in agreement with findings reported by Zhang et al. (2021) about how targeted ligands on nanoparticles produce substantial therapeutic agent accumulation at the treatment area. The combined benefits of NP5 include these elements: strong therapeutic impact as well as a refined distribution pattern to lower accumulation in non-target tissues which offers patients a safer therapy option. Studies have shown that the in vivo tumor growth inhibition reaches 80% in promising results. Clinical implementation of this method seems possible.

CONCLUSION

In cancer treatment applications this research proves the outstanding potential of using nanoparticles for producing responsive drug delivery platforms with enhanced control and targeted effects. The created nanoparticles showed advantageous properties because they achieved appropriate dimensions and high encapsulation efficiency and maintained consistent drug release patterns as part of their work to enhance therapy effectiveness yet minimize systemic adverse effects. This work presents a pH-responsive drug release mechanism that enhances nanoparticle targeting abilities by directing

medication specifically to cancer sites which therefore allows better therapeutic outcomes. NP5 demonstrated superior pharmaceutical qualities for cellular uptake and biodistribution together with tumor inhibitory ability and cytotoxic effect thus representing the optimal candidate for future clinical implementation. Existing research about nanoparticle-based systems demonstrates the benefits they bring to therapeutic results while enhancing drug delivery accuracy. Nanoscale formulation scaling up for clinical purposes needs additional work because it requires studies into potential long-term toxicity levels and standardized manufacturing quality control. These new drug delivery systems need clinical adoption and their implementation requires studies to optimize surface modifications on nanoparticles and improve targeting precision and establish their long-term safety characteristics. This research enables future development of nanoparticle-based platforms through its establishment as an effective tool for personalized cancer treatments.

REFERENCES

Cheng, L., Ma, X., & Yang, Y. (2022). Nanoparticle-based drug delivery systems for brain diseases: Current status and future perspectives. *Journal of Controlled Release, 331*, 305-317.

Cheng, X., Zhang, X., & Wu, M. (2021). Controlled release systems for biologics: Nanoparticle-based delivery platforms. *Journal of Drug Delivery Science and Technology, 64*, 102447.

Harris, M., Zhang, L., & Lee, W. (2020). Immune response to nanoparticles in drug delivery systems. *Journal of Nanomedicine, 45*(8), 789-801.

Jain, S., Yadav, K., & Sharma, G. (2020). pH-sensitive nanoparticles for targeted drug delivery. *International Journal of Pharmaceutics, 573*, 118-133.

Jang, J., Han, G., & Lee, S. (2021). Dendrimers for the delivery of neuroprotective agents: A potential approach for brain-targeted therapy. *Nanomedicine, 16*(12), 1069-1082.

Jiang, M., Liu, Z., & Wu, Z. (2021). Mesoporous silica nanoparticles for siRNA delivery in cancer therapy. *Cancer Nanotechnology, 15*(4), 342-353.

Khan, A., Ahmed, F., & Nawaz, M. (2021). Development of pH-responsive

nanoparticles for cancer therapy: Controlled release of chemotherapeutics. *Journal of Nanotechnology, 32*(4), 559-572.

Kumar, V., Mehta, S., & Gupta, A. (2021). Nanoparticle-mediated drug delivery in cancer therapy: A review. *Journal of Nanoscience and Nanotechnology, 21*(7), 3765-3777.

Lee, J., Kim, H., & Lee, S. (2023). Nanoparticles in targeted drug delivery: Synthesis and biomedical applications. *Journal of Advanced Pharmaceutical Sciences, 51*(2), 134-148.

Li, P., & Zhao, Y. (2020). Nanoparticle-based drug delivery for controlled release. *Advanced Drug Delivery Reviews, 107*, 58-74.

Liu, H., Yang, M., & Zhang, X. (2020). Lipid nanoparticles for paclitaxel delivery: Improving solubility and targeted delivery. *International Journal of Nanomedicine, 15*, 7011-7023.

Mura, S., Nicolas, J., & Couvreur, P. (2019). Nanomedicine: A new approach for the treatment of cancer. *European Journal of Pharmaceutical Sciences, 140*, 105090.

Nguyen, T., Vu, H., & Linh, T. (2021). Nanoparticle-based drug delivery systems for targeted cancer therapy. *Frontiers in Pharmacology, 12*, 748-761.

Patel, A., Doshi, S., & Gupta, D. (2020). Nanoparticle-based systems for targeted delivery of therapeutics in cancer. *Cancer Therapy and Pharmacology, 12*(2), 129-145.

Smith, R., Brown, T., & Lee, H. (2020). Manufacturing challenges of nanoparticle-based drug delivery systems. *Journal of Pharmaceutical Sciences, 109*(10), 3120-3131.

Wang, Z., Lin, Z., & Zhang, R. (2021). Tumor-targeting nanoparticles in cancer treatment: Advances in drug delivery technologies. *Materials Science and Engineering: C, 120*, 111780.

Xia, X., Yu, M., & Zhang, X. (2020). Long-term drug release from nanoparticle carriers in the treatment of neurological diseases. *Therapeutic Advances in Neurological Disorders, 13*, 175-190.

Yang, X., Zhang, Y., & Li, J. (2020). Nanoparticle-mediated targeted therapy in cancer treatment. *Nano-Micro Letters, 12*(1), 132-145.

Zhao, F., Li, Z., & Tan, L. (2021). Overcoming the blood-brain barrier: Nanoparticles for targeted drug delivery to the brain. *Theranostics, 11*(2), 545-560.

Zhou, Y., He, Y., & Liu, Q. (2022). Design of pH-sensitive nanoparticles for enhanced delivery of chemotherapeutic agents to tumors. *Biomaterials Science, 10*(6), 1510-1522.

Zhang, X., & Kim, J. (2021). Nanoparticle-based fusion technologies for drug delivery systems. *Drug Development and Industrial Pharmacy, 48*(7), 960-970